Trial Profile

A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Mar 2018 The protocol was amended to enroll an additional 20 patients in a high-dose temozolomide cohort (200 mg/m2/d orally on days 1-5 of each 28-day cycle), according to result published in the Cancer.
26 Mar 2018 Primary endpoint (Disease control rate) has been met, according to results published in the Cancer.
26 Mar 2018 Results (n=75) assessing the efficacy and tolerability of temozolomide [Temodar] + veliparib [ABT-888; Abbott Laboratories] in patients heavily pretreated, metastatic with colorectal cancer, were published in the Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com